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Abstract 
 
Objectives: BRIDGE-II-MIX study aimed to estimate the frequency of mixed states 
in patients with MDE according to different definitions. This post-hoc analysis 
evaluates the association between obesity and the presence of mixed features and 
bipolarity. Methods: 2811 MDE subjects were enrolled in this multicentre cross-
sectional study. In 2744 patients, the body mass index (BMI) has been evaluated. 
Psychiatric symptoms, socio-demographic and clinical variables were collected, 
comparing the characteristics of MDE patients with (MDE-OB) and without obesity 
(MDE-NOB). Results: obesity (BMI ≥30) was registered in 493 patients (18%). In the 
MDE-OB group, 90 patients (20%) fulfilled DSM-IV-TR criteria for BD, 225 patients 
(50%) fulfilled the criteria for bipolarity specifier, 59 patients (13%) fulfilled DSM-5 
criteria for MDE with mixed features and 226 patients (50%) fulfilled Research-Based 
Diagnostic Criteria for a mixed depressive episode. Older age, history of (hypo)manic 
switches during antidepressant treatment, the occurrence of three or more MDEs, 
atypical depressive features, antipsychotic treatment, female gender, depressive mixed 
state according to DSM-5 criteria, comorbid eating disorders and anxiety disorders 
were significantly associated with MDE-OB group. Among (hypo)manic symptoms 
during the current MDE, psychomotor agitation, distractibility, increased energy and 
risky behaviors were the variables most frequently associated with MDE-OB group. 
Conclusions: In our sample, the presence of obesity in patients with MDE seems to be 
associated with a lifetime diagnosis of BD. These findings suggest that obesity in 
patients with MDE could be considered a possible marker of bipolarity. 
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1. Introduction 
One of the main challenges in the diagnostic assessment of mood disorders is the early 
detection of bipolarity and mixed features in patients with a major depressive episode 
(MDE), in order to distinguish unipolar depression from bipolar disorder (BD), with 
relevant clinical and treatment implications [1, 2]. In fact, several epidemiological and 
clinical studies reported that almost 40% of BD patients initially receive the incorrect 
diagnosis of major depressive disorder (MDD) [3-5]. In primary care settings, a 
careful screening for mixed features allows to the identification of BD in 21% to 26% 
of unipolar depressed patients [6, 7]. In the Bridge study on 5635 adults with an 
ongoing MDE, a total of 903 patients fulfilled DSM-IV-TR criteria for BD, whereas 
2647 met the bipolarity specifier criteria [8-10]. Growing evidence suggests an 
increased prevalence of mood disorders and in particular BD among individuals who 
are overweight or obese compared to those with weight in the normal range [11, 12]. A 
relationship between depression, especially with atypical features, and obesity has 
been widely demonstrated [13-15]. Moreover, atypical symptoms in depressed patients 
have been associated with both obesity and BD [16]. Notably, obese (OB) patients 
have been shown to have a higher risk of developing MDD and BD [17]. On the other 
hand, the course of bipolar depression is frequently affected by the development of 
overweigh and obesity, that could be related to the effects of psychotropic medications 
or comorbid diagnosis with eating disorders such as binge eating disorder (BED) [12, 
18].  
A recent meta-analysis of 9 cross-sectional epidemiological studies confirmed that 
obesity is associated with increased prevalence of BD, however the mechanisms and 
temporal sequence underlying this relationship are poorly understood [19]. Regarding 
gender differences, women showed higher rates of atypical features, as well as a 
higher body mass index (BMI) than males, especially abdominal obesity [16]. 
Furthermore, the rate of obesity in women with BD has found to be higher than in men 
with BD [20]. The co-occurrence of BD and obesity seems to negatively affect the 
course and the long-term prognosis of BD [21]. Greater number of lifetime depressive 
and manic episodes, more severe and difficult-to-treat index affective episode, higher 
affective recurrence, predominantly depressive, and shorter time to relapse were more 
frequently reported in OB than in non-obese (NOB) BD patients [22]. A recent study 
sample of 571 consecutive patients with MDE suggested that obesity could be 
considered as a predictor of bipolarity [23].  However, to our knowledge, the 
prevalence of mixed features, according to the definition of the DSM-5 and the 
research based diagnostic criteria (RBDC), and bipolarity, according to the criteria of 
the specifier for bipolarity and the DSM-IV-R for BD, in OB and NOB patients with 
MDE has not been systematically investigated. 
The objective of Bipolar Disorders: Improving Diagnosis, Guidance and Education 
(BRIDGE)-II-MIX [24-26] naturalistic study was to provide a reliable estimate of the 
frequency of mixed states in a large international sample of patients diagnosed with 
MDE according to several sets of criteria.  
The aim of the present post-hoc analysis is to compare the characteristics of patients 
diagnosed with MDE who present a BMI ≥30 (MDE-OB) and patients with BMI <30 
(MDE-NOB). We aim to characterize the MDE-OB patients in order to clarify the 
correlation between mixed features, bipolarity and obesity. We will also discuss the 
possible clinical and treatment implications of this association. 
2. Patients and methods 
The BRIDGE-II-Mix Study was a multicentre, international, non-interventional, cross-
sectional study. The recruitment procedure and the inclusion criteria have been 
described in a previous study [24]. From an initial pool of 2811 patients with MDE, 
BMI has been evaluated in 2744 patients. 493 (18%) patients presented a BMI ≥30. 
 
2.1 Data collection 
In a single consultation the participating psychiatrists completed a case report form for 
each patient, incorporating inclusion criteria, socio-demographic variables (age, 
gender, marital status), biometrics values (height, weight), in- or out- patient status, 
history of psychiatric symptoms (mood symptoms, suicide attempts) and previous 
psychiatric hospitalizations. Features of the MDE, including bipolar symptoms listed 
in the DSM-IV-TR diagnostic criteria for BD, known risk factors for BD (e.g. family 
history of BD, early onset depression), previous response to ADs, psychiatric 
comorbidity, current treatment and functional status determined by the investigator 
using the Global Assessment of Functioning (GAF) were assessed [27]. 
The evaluation packet was explicitly structured to use skills that fully trained 
psychiatrists would have and routinely apply in conducting an initial evaluation of an 
acutely ill patient. No rating scales requiring calibration with a standard were 
incorporated. Raters were instructed to follow their usual practice, as training might 
have altered these practices and been seen as a biasing factor. 
The primary objective of the BRIDGE-II-MIX study was to establish the frequency of 
depressive mixed states by analyzing all the relevant symptoms of either pole. After 
the publication of DSM-5, this was post-hoc defined as 1) the proportion of patients 
fulfilling DSM-5 criteria for MDE with mixed features (DSM-5-MXS) [28], and 2) 
research based diagnostic criteria for  mixed state (RBDC-MXS). RBDC-MXS are 
defined by the presence of MDE plus 3 out of the following 14 hypomanic symptoms 
for at least a week: Irritable mood, Emotional/mood lability, Distractibility, 
Psychomotor agitation, Impulsivity, Aggression (verbal or physical), Racing thoughts, 
More talkative/pressure to keep talking, Hyperactivity, Increased energy, Risky 
behavior, Grandiosity, Elation, Hyper-sexuality. The proportion of patients fulfilling 
criteria for BD according to the DSM-IV-TR and bipolarity specifier proposed by 
Angst et al. [5, 8, 9] was also identified. The bipolarity specifier attributes a diagnosis 
of BD to patients who experienced an episode of elevated mood or irritable mood or 
increased activity with at least three of the symptoms listed under Criterion B of the 
DSM-IV-TR, associated with at least one of the three following consequences: (i) 
unequivocal and observable change in functioning uncharacteristic of the person’s 
usual behavior, (ii) marked impairment in social or occupational functioning 
observable by others or (iii) requiring hospitalization or outpatient treatment. No 
minimum duration was required and no exclusion criteria were applied. 
 
2.2 Statistical analysis 
Chi-square test was used for comparison between groups for categorical variables and 
Student’s t-test for continuous variables. The univariate analysis involved many tests 
of statistical significance, raising the problem of type I errors. For this reason, we 
corrected for multiple comparisons and utilized a Bonferroni-corrected threshold for 
statistical significance. A stepwise backward logistic regression model was then used 
to identify the predictive value of the 14 current (hypo)manic symptoms on the 
presence of BMI ≥30. The stepwise modeling procedure started with the full model 
and consisted, for each step, in eliminating the least statistically significant variable 
from the model and re-computing the revised model, until all remaining variables were 
at p<.1. Odds ratios with 95% confidence intervals were used for observed 
associations. We used the statistical routines of SPSS Statistics 22.0 for Mac OS 
(SPSS Inc., USA). 
3. Results 
3.1 Differences in clinical variables between MDE-OB and MDE-NOB 
According to the DSM-IV-TR criteria, a diagnosis of BD was detected more 
frequently in the MDE-OB group (19.9%) compared to the MDE-NOB group (15.8%) 
(p =0.033). Considering the BD subtypes, a statistically significant difference was 
found regarding the diagnosis of BD-I, with prevalence rates of 14.1% in the MDE-
OB group and 9.3% in the MDE-NOB group (p =0.002). Conversely, there were no 
significant differences in the prevalence rates of BD-II subtype between the two 
groups. Regarding the frequency of mixed depression, 59 (13%) patients in the MDE-
OB group and 151 (6.6%) in MDE-NOB group fulfilled the DSM-5 criteria for mixed 
states (p <0.001). In addition, when RBDC criteria for Mixed Episode were applied, 
MDE-OB patients reported more frequently mixed features than MDE-NOB subjects 
(p <.001). The two groups significantly differed for age, with MDE-OB patients 
resulting older than MDE-NOB subjects (p <0.001). Female gender was significantly 
more prevalent in the MDE-OB group than in the MDE-NOB group (p =0.001). MDE-
OB patients were more frequently married than MDE-NOB subjects (p <0.001). 
MDE-OB patients had significantly higher rates of first-degree family history for BD 
compared to subjects in the MDE-NOB group (p <0.001). MDE-OB patients presented 
more frequently psychotic features (p <0.001) and atypical features (p <0.001) than 
MDE-NOB patients. Moreover, MDE-OB patients reported more frequently three or 
more lifetime depressive episodes (p <0.001), history of suicide attempts (p =0.026) 
and current episode that lasts more than one month (p =0.011) compared to the MDE-
NOB subjects (Table 2). Regarding the psychiatric comorbidity, there were no 
statistically significant differences between the two groups with respect to the rates of 
alcohol-substance use disorders, ADHD and borderline personality disorder. Eating 
disorders and anxiety disorders were significantly more frequent in the MDE-OB 
group in comparison to the MDE-NOB group [respectively 11.8% vs 6.1% (p <0.001) 
and 34.0% vs 27.6% (p =0.006)]. With respect to previous pharmacological 
treatments, MDE-OB patients were treated with more than three drugs contemporarily 
more frequently than the MDE-NOB patients (p <0.001). Furthermore, they were more 
frequently prescribed antipsychotics (p <0.001) and mood stabilizers (p <0.001) than 
the MDE-NOB subjects. There were no statistically significant differences regarding 
AD treatment and benzodiazepines prescriptions between the two groups. As concern 
the past response to treatment with ADs, MDE-OB patients have presented more 
(hypo)manic switches compared to MDE-NOB subjects (p <0.001). After the 
multivariate logistic regression analysis, the variables most strongly associated with 
the presence of obesity were age [p <0.001; OR 1.02 (1.01-1.02)], history of 
(hypo)manic switches during AD treatment [p =0.005; OR 1.46 (1.12-1.90)], 
comorbid anxiety disorders [p =0.049; OR 1.26 (1.00-1.60)], antipsychotics treatment 
[p =0.025 OR 1.29 (1.03-1.62)], marriage [p <0.001; OR 1.48 (1.19-1.84)], female 
gender [p =0.004; OR 1.43 (1.12-1.82)]; atypical features [p =0.002; OR 1.78 (1.24-
2.54)], comorbid eating disorders [p = 0.010; OR 1.61 (1.12-2.32), psychotic features 
[p =0.39; OR 1.44 (1.02-2.05)], occurrence of three or more MDEs [p =0.003; OR 
1.44 (1.13-1.82)], ,  and depressive mixed state according to DSM-5 criteria [p =0.019; 
OR 1.52 (1.07-2.15)] (Table 3). 
3.2 Differences in the frequency of (hypo)manic symptoms between MDE-OB and 
MDE-NOB 
The MDE-OB patients showed 11 out of the 14 RBDC (hypo)manic symptoms with a 
significantly higher prevalence compared to the MDE-NOB patients (p <0.001) (Table 
4). In multivariate logistic regression analysis, (hypo)manic symptoms most strongly 
associated with obesity were psychomotor agitation, distractibility, increased energy 
and risky behavior (Table 5). 
4. Discussion 
In our multinational sample of 2744 patients with MDE, obesity resulted to be 
relatively common (18%), in line with the results of previous studies, supporting the 
strong association between depression and obesity [23, 29-31]. Interestingly, we 
observed a significant association between BD and obesity, similarly to previous 
findings [19, 32]. In our sample, the frequency of BD varied substantially according to 
different diagnostic criteria. When bipolar specifier was applied, about half of the 
MDE-OB subjects presented BD in comparison with approximately 40% of MDE-
NOB patients. We found that obesity was significantly associated with the presence of 
atypical depressive features [14, 33]. Symptoms such as leaden paralysis, increased 
appetite, overeating, oversleeping and reduced physical activity might explain the 
weight gain in atypical depressive patients [34]. Atypical features have been 
associated with both BD and BED [35]. Thus, the specific association between BD and 
obesity might be partly explained by these overlapping atypical symptoms. Our results 
also showed a relationship between obesity and female gender in MDE patients, 
similarly to previous findings [36]. Interestingly, women present more frequently 
depression with atypical features [16] and this association could represent the link 
between obesity and female gender.  The relationship between obesity and BD has 
been associated with a predominant depressive polarity of BD [22, 37, 38]. Similarly, 
in our sample obesity was associated with a history of more than three previous 
MDEs, supporting the relevant role of depression in developing overweight. MDE-OB 
patients were more frequently married than MDE-NOB, maybe due to older age of this 
group of patients. Moreover,the positive relationship that we found between MDE-OB 
patients and older age, reported also in previous studies [32, 39, 40], could be partially 
explained by the exposure to psychopharmacological treatment over a longer time 
period [41-43]. Noteworthy, in our sample antipsychotic treatment was significantly 
more frequent in MDE-OB group. Antipsychotics are known to be associated with 
obesity [44], even if other studies reported that about 40% of drug-naïve BD patients 
were obese or overweight [37]. Since BD-I patients are more likely to be treated with 
antipsychotics/mood stabilizers compared to BD-II patients [45], in our sample the 
higher prevalence of BD-I diagnosis in MDE-OB patients in comparison to BD-II 
diagnosis could be related to the psychotropic medications. However, there are 
insufficient data to define how much psychotropic treatment is associated with 
overweight in BD patients [46]. With regard to lifetime comorbid diagnosis, in 
accordance with the existing literature [47-49], we found that comorbidity with eating 
disorders and anxiety disorders was more frequently reported in MDE-OB patients 
than in MDE-NOB subjects. A recent post-hoc analysis of the BRIDGE-II-mix 
showed that comorbidities with eating disorders and anxiety disorders were more 
frequently associated with a BD diagnosis (50). In this sense, a possible association 
between obesity, eating disorders and bipolar spectrum disorders could be 
hypothesized, in line with previous findings [49]. This comorbidity has been 
associated with increased severity of eating behaviors, poorer prognosis for obesity 
and treatment resistance in BD [22, 49, 51]. In our sample, first-degree family history 
for BD, antidepressant-induced (hypo)manic switches and psychotic features were 
more frequent in MDE-OB patients than in MDE-NOB patients. Moreover, regardless 
of the diagnostic criteria applied, the presence of mixed features was significantly 
more prevalent in the MDE-OB patients than in MDE-NOB subjects. After the 
multiple logistic regression, DSM-5 mixed features resulted as the most significantly 
variable correlated with obesity. Taken together, these results might support the 
hypothesis of relationship between obesity and the bipolar spectrum. It has been 
suggested that the presence of lifetime (hypo)manic symptoms and mood instability 
may lead to impulsive-addictive behaviors, such as uncontrolled eating [23]. In our 
sample, most of the RBDC (hypo)manic symptoms were more prevalent in the MDE-
OB group compared to the MDE-NOB subjects. This association could represent a 
possible link between bipolar spectrum disorders and obesity.  
The main strengths of the BRIDGE-MIX II study include the large sample size, and 
the wide range of care settings, both hospital and community, from eight countries 
across three continents. Narrow exclusion criteria help making the findings more 
generalizable. The major limitation is that the participating centres were not randomly 
selected, which may led to a bias through the inclusion of psychiatrists with a 
particular interest in mixed states. Furthermore, among comorbid eating disorders, the 
BED subtype was not specified. Moreover, the lack of complete biometric data (waist 
circumference) might lead to an under-detention of abdominal obesity, especially in 
women. 
 
5. Conclusion 
From the results of our study, MDE-OB seems to show higher rates of bipolarity and 
mixed features than MDE-NOB individuals, indicating that obesity could be 
investigated as a possible biomarker of bipolar spectrum disorders. The identification 
of individuals with MDE and obesity as subset of patients at higher risk of presenting 
mixed and hypomanic symptoms should lead to a more comprehensive clinical 
evaluation in order to achieve a prompt detection of bipolar spectrum disorders, with 
important clinical and treatment implications, such as tailored behavioral 
psychological interventions [52]. Further longitudinal data on different populations are 
necessary to better define the burden and the role of the association between obesity 
and mood disorders on correct diagnosis, treatment response and clinical outcome. 
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 Table 1. Diagnostic distribution and frequency of mixed states and bipolarity according to different 
definition in 2744 patients with a Major Depressive Episode with (MDE-OB) and without (MDE-NOB) BMI 
≥30. 
 
MDE-NOB 
(n = 2291) 
MDE-OB 
(n = 493) 
OR (95% CI ) p 
Diagnostic Distribution of Bipolar Disorder 
DSM-IV Bipolar 362 (15.8%) 90 (19.9%) 1.32 (1.02-1.71) .033 
- DSM-IV Bipolar I 213 (9.3%) 64 (14.1%) 1.61 (1.19-2.17) .002 
- DSM-IV Bipolar II 149 (6.5%) 26 (5.7%) 0.88 (0.57-1.35) ns 
Bipolar Specifier 920 (40.1%) 225 (49.7%) 1.47 (1.20-1.80) <.001 
- Bipolar I Specifier 526 (22.9%) 164 (36.2%) 1.90 (1.54-2.36) <.001 
- Bipolar II Specifier 394 (17.2%) 61 (13.5%) 0.75 (0.56-1.00) ns 
Depressive Mixed State 
DSM-5 criteriaa 151(6.6%) 59 (13.0%) 2.12 (1.54-2.92) <.001 
RBDC Mixed Depressionb 929 (40.5%) 226 (49.9%) 1.46 (1.19-1.79) <.001 
Legend.
 a 
MDE + three non-overlapping hypomanic criteria; 
b 
MDE + three or more hypomanic symptoms. 
Abbreviations. BMI: body mass index; RBDC: research based diagnostic criteria. 
 
 Table 2. Clinical Features in 2744 patients with a Major Depressive Episode with (MDE-OB) and without 
(MDE-NOB) BMI ≥30. 
 MDE-NOB 
(n = 2291) 
MDE-OB 
(n = 493) 
OR (95% CI ) p 
Age, mean (S.D.) 43.4 (13.9) 47.1 (12.4) t=5.38 <0.001 
Gender, Female  1547 (67.5%) 342 (75.5%) 1.48 (1.18-1.87) .001 
Marital status, Married 1186 (51.7%) 281 (62.0%) 1.52 (1.24-1.87) <0.001 
First-Degree Family History of BD 317 (14.0%) 93 (20.7%) 1.60 (1.25-2.07) <.001 
(Hypo)manic switches with ADs 340 (14.8%) 117 (25.8%) 1.99 (1.57-2.54) <.001 
Psychotic Features 564 (24.6%) 157 (34.7%) 1.63 (1.31-2.01) <.001 
Atypical Features 132 (5.8%) 57 (12.6%) 2.36 (1.70-3.27) <.001 
Suicide Attempts 490 (21.4%) 119 (26.3%) 1.31 (1.04-1.65) .026 
≥3 MDE 1242 (54.2%) 316 (69.8%) 1.95 (1.57-2.42) <.001 
Current Episode >1 month  779 (34.0%) 183 (40.4%) 1.31 (1.07-1.61) .011 
First MDE <30 Years 1119 (52.2%) 231 (51.0%) 0.95 (0.78-1.17) ns 
Psychiatric comorbidity 
Anxiety Disorders 632 (27.6%) 154 (34.0%) 1.35 (1.09-1.68) .006 
Eating Disorders 138 (6.1%) 53 (11.8%) 2.07 (1.48-2.89) <.001 
Alcohol-Substance Use Dis. 199 (8.7%) 32 (7.1%) 0.80 (0.54-1.78) Ns 
ADHD 49 (2.2%) 12 (2.7%) 1.25 (0.66-2.36) Ns 
Borderline Personality Disorder 143 (6.2%) 39 (8.6%) 1.42 (0.98-2.05) Ns 
Previous treatments 
Antidepressants 1874 (81.8%) 374 (82.6%) 1.06 (0.81-1.38) ns 
Antipsychotics 748 (32.6%) 199 (43.9%) 1.62 (1.32-1.99) <.001 
Mood-Stabilizers 606 (26.4%) 168 (37.1%) 1.64 (1.32-2.02) <.001 
More than 3 drugs 707 (30.8%) 190 (41.9%) 1.62 (1.32-1.99) <.001 
Benzodiazepines 1046 (45.6%) 212 (46.8%) 1.05 (0.85-1.28) ns 
Abbreviations. ADs: antidepressants; ADHD: attention deficit and hyperactivity disorders; BD: bipolar disorder; BMI: body mass index. 
 Table 3. Multiple logistic regression backward procedure of clinical features, bipolarity and mixed state diagnosis on the presence of BMI ≥30 in 
2744 subjects with Major Depressive Episode (MDE). 
Variables in equation Wald p-value OR (95% CI) 
Age 14.525 <.001 1.02 (1.01-1.02) 
(Hypo)manic switches with Ads 7.848 .005 1.46 (1.12-1.90) 
Anxiety Disorders 3.860 .049 1.26 (1.00-1.60) 
Antipsychotics 5.045 .025 1.29 (1.03-1.62) 
Marital status, Married 12.310 .000 1.48 (1.19-1.84) 
Gender, Female 8.453 .004 1.43 (1.12-1.82) 
Atypical Features 9.993 .002 1.78 (1.24-2.54) 
Eating Disorders 6.580 .010 1.61 (1.12-2.32) 
Psychotic Features 4.251 .039 1.44 (1.02-2.05) 
≥3 MDE 8.99 .003 1.44 (1.13-1.82) 
Depressive mixed state (DSM-5) 5.467 .019 1.52 (1.07-2.15) 
Legend. Wald = 227.909, df = 1, p <.001. Variables not included in the equation: more than 3 drugs, current episode >1 month, first-degree family history of BD, suicide 
attempts, mood-stabilizers. 
Abbreviations. ADs: antidepressants; BMI: body mass index. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Abbreviations. BMI: body mass index. 
 
 
 
 
 
 
  
Table 4: Distribution of 14 current (hypo)manic symptoms in 2744 patients with  a Major Depressive Episode 
with (MDE-OB) and without (MDE-NOB) BMI ≥30. 
 
MDE-NOB 
(n = 2291) 
MDE-OB 
(n = 493) 
OR (95% CI ) p 
Irritable mood 720 (31.4%) 181 (40.0%) 1.45 (1.18-1.79) <.001 
Emotional/mood lability 674 (29.4%) 153 (33.8%) 1.22 (0.99-1.52) ns 
Distractibility 525 (22.9%) 151 (33.3%) 1.68 (1.35-2.09) <.001 
Psychomotor agitation 330 (14.4%) 111 (24.5%) 1.93 (1.51-2.46) <.001 
Impulsivity 306 (13.4%) 98 (21.6%) 1.72 (1.39-2.31) <.001 
Aggression (verbal or physical) 298 (13.0%) 91 (21.0%) 1.78 (1.37-2.29) <.001 
Racing thoughts 246 (10.7%) 81 (17.9%) 1.81 (1.38-2.38) <.001 
More talkative/pressure to keep talking 238 (10.4%) 79 (17.4%) 1.82 (1.38-2.40) <.001 
Risky behaviour 147 (6.4%) 56 (12.4%) 2.06 (1.49-2.85) <.001 
Hyperactivity 164 (7.2%) 60 (13.2%) 1.98 (1.45-2.71) <.001 
Increased energy 137 (6.0%) 52 (11.5%) 2.04 (1.46-2.86) <.001 
Grandiosity 82 (3.6%) 23 (5.1%) 1.44 (0.89-2.32) ns 
Euphoria 97 (4.2%) 32 (7.1%) 1.72 (1.14-2.59) .013 
Hyper-sexuality 57 (2.5%) 17 (3.8%) 1.53 (0.88-2.65) ns 
 Table 5. Multiple logistic regression backward procedure of 14 current (hypo)manic symptoms on the presence of BMI ≥30 in 2744 
subjects with Major Depressive Episode (MDE). 
Variables in equation Wald p-value OR (95% CI) 
Psychomotor agitation 8.180 .004 1.50 (1.13-1.97) 
Distractibility 5.693 .017 1.34 (1.05-1.71) 
Increased energy 3.897 .048 1.44 (1.00-2.08) 
Risky behaviour 2.845 .092 1.37 (0.95-1.97) 
 
Legend. Wald = 801.99, df = 1, p <.001. Variables not included in the equation: irritable mood, mood lability, impulsivity, racing thoughts, hyper-sexuality, aggression, more 
talkative/pressure to keep talking, hyperactivity, grandiosity, euphoria.  
Abbreviations. BMI: body mass index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
